Dendreon Pharmaceuticals and Shoreline Biosciences: manufacturing alliance
Dendreon Pharmaceuticals and Shoreline Biosciences have announced a CNC and manufacturing alliance. According to the companies, the collaboration will center on advancing iPSC-derived cellular therapies.
“With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, Dendreon is well positioned to support Shoreline in manufacturing from Phase I clinical trials through commercialization,” said Maria Cho, vice president of business development and corporate strategy. “We are thrilled to partner with Shoreline to enable the future of cell therapy and change the way serious diseases are treated.”
